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Effects of somatostatin on phosphate transport: Evidence for the rote of
basal insulin. Previous studies suggest that normoglycemic hyperinsu-
linemia is associated with enhanced proximal tubule and overall renal
phosphate (P04) reabsorption. It is unclear whether the basal level of
insulin also regulates P04 transport. Furthermore, the role of parathy-
roid hormone, the associated antinatriuresis, and the distal nephron is
uncertain. To examine these issues, clearance and recollection micro-
puncture studies were performed in volume-expanded parathyroidecto-
mized rats. Infusion of des-Asn5-D-Trp8-D-Ser'3, a somatostatin ana-
logue highly selective for insulin at 10 gIkg/hr, decreased plasma
insulin (12.6 to 2.8 U/ml), and increased plasma glucose (93 to 140
mg%) and fractional excretion (FE) of sodium (A = 2.5%). The
clearance of P04 (118 to 297 dImin) and FEB04 (2.4 to 6.8%) was
increased. Continued somatostatin infusion produced a sustained phos-
phaturia whereas the addition of insulin (0.10 U/kg/hr) abolished the
phosphaturic effects. Separate loading with saline and glucose to
achieve comparable AFENa (2.9%) and Aplasma glucose (52 mg%) did
not increase P04 excretion. Between basal and experimental phases,
there was no difference in plasma ultrafiltrable P04, GFR, or segmental
fluid reabsorption. While fractional delivery of P04(FD04) was un-
changed in the control, somatostatin increased FD04 to late proximal
(50 vs. 32%), early distal (28.2 vs. 13.4%), late distal tubules (11.8 vs.
6.4%), and to the urine (8.5 vs. 4.9%). These data indicate that (I)
insulin deficiency, as produced by somatostatin infusion, impairs
tubular P04 reabsorption, suggesting an important role for the basal
level of insulin in renal P04 homeostasis; (2) the phosphaturia of
somatostatin is independent of the concomitant natriuresis, hyperglyce-
mia, PTH, and changes in plasma P04; and (3) insulinopenia reduces
P04 transport in the proximal convoluted tubule and the distal nephron.
Effets de Ia somatostatine sur le transport du P04: Preuve d'un role de
l'insuline basale. Des etudes antérieures suggerent que l'hyperinsuliné-
mie normoglycémique est associée a une augmentation de Ia réabsorp-
tion rCnale de phosphate (P04) globale et dans le tubule proximal. On ne
sait pas bien site niveau basal d'insuline regule egalement le transport
de P04. En outre, le role de l'hormone parathyroldienne, de l'antina-
triurése associée et du néphron distal est incertain. Afin d'examiner ces
possibilités, des etudes de clearance et de microponction avec recollec-
tion ont éte effectuées chez des rats parathyroldectomisés en expansion
volemique. La perfusion de des-Asn5-D-Trp8-D-Ser'3, un analogue de Ia
somatostatine hautement sélectif pour l'insuline a 10 .tg/kgIhr, a di-
minué l'insuline plasmatique (12.6 a 2.8 .tUlml), augmenté La glycémie(de 93 a 140 mg%) et l'excrétion fractionnelle (FE) de sodium (A =
2.5%). La clearance de P04 (118 a 297 lImin) et FE1,04 (2.4 a 6.8%) se
sont élevées. Une perfusion prolongée de somatostatine a entraIné une
phosphaturie persistante tandis que l'addition d'insuline (0.10 Ulkglhr)
a aboli les effets phosphaturiants. Une charge séparée avec du solute
sale et du glucose pour obtenir un A FENa (2.9%) et un A glycemie (52
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mg%) comparables n'a pas augmenté l'excrétion de P04. Entre les
phases basale et experimentale il n'y avait pas de difference dans le PU4
ultrafiltrable, le GFR ni Ia reabsorption segmentaire de fluide. Tandis
que Ia fraction délivrée de P04(FD1,04) était inchangee pendant le
contrOle, Ia somatostatine a augmente FD1,04 aux tubules proximal
tardif (50 contre 32%), distal précoce (28.2 contre 13.4%) et tardif (11.8
contre 6.4%), et a l'urine (8.5 contre 4.9%). Ces données indiquent que
(1) Ia carence en insuline resultant d'une perfusion de somatostatine
altére La reabsorption tubulaire de P04, suggérant un rOle important de
Ia concentration de l'insuline de base dans l'homéostasie du P04; (2) Ia
phosphaturie due a Ia somatostatine est independante de La natriurèse
concomitante, de l'hyperglycémie, de Ia PTH, et des modifications du
P04 plasmatique; (3) l'insulinopénie réduit le transport de P04 dans le
tubule contourné proximal et le nephron distal.
Previous studies in intact humans [1—2], dog [3], and rat [4]
suggest that hyperinsulinemia is associated with enhanced renal
P04 reabsorption, characterized by increased proximal tubule
transport [3]. Because there was a concomitant antinatriuresis
[2, 3] or antidiuresis [1], and because glucose was administered,
it is uncertain as to the role played by endogenous parathyroid
hormone (PTH), exogenous glucose load, and the changes in
renal handling of sodium. Furthermore, it is not clear whether
the antiphosphaturic phenomenon of hyperinsulinemia is mir-
rored by a phosphaturic effect of insulin deficiency. The objec-
tives of the present investigation were to examine these issues
and to evaluate tubular P04 transport in response to a reduction
in plasma insulin levels.
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Methods
Male Sprague-Dawley rats weighing 275 to 375 g were used.
Parathyroidectomy (PTX) was performed and confirmed as
previously described [5]. Both before and after PTX, the rats
were fed a 0.6% phosphorus diet, At least 8 days were allowed
to elapse over which weight gain was documented before
experiments were initiated. These PTX rats were divided into
six groups as follows:
Group 1: effects of somatostatin on P04 excretion (N = 12).
Clearance experiments were performed using standard tech-
niques as previously described [5, 6] during sustained infusion
with sodium chloride (150 mM containing 6 mg% Ca) at a rate of
10 ml/100 g/hr. This degree of extracellular fluid volume expan-
sion was felt necessary to rapidly achieve a relatively steady
state to minimize time-associated changes in tubular fluid and
sodium handling in the course of recollection micropuncture
experiments that lasted 5 to 6 hr (see groups 5 and 6 below).
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Fig. 1. Effects of somatostatin on plasma and clearance data. Abbrevi-
ation and symbol are: C, basal phase before somatostatin; , indicates
significant difference of P < 0.01 compared to the basal phase. P values
given refer to differences due to the presence of concomitant insulin;
NS, not significant.
After equilibration for 90 mm, four 20-mm urine collections
were made for the basal phase. In the succeeding experimental
phase, an analogue of somatostatin, des-Asn5-D-Trp8-D-Ser'3
(kindly supplied by Drs. J. Rivier and M. Brown of Salk
Institute, LaJolla, California), known to be highly selective in
suppressing insulin [7, 8], was infused at 10 g/kg!hr in the same
infusate for 4 hr. After that, in half of the group, the somato-
statin was continued for 2 more hr, while in the remaining half,
regular insulin (Iletin, Eli Lilly, Indianapolis, Indiana) was
added in the infusate to deliver 0.1 U/kg/hr for 2 hr. Arterial
blood and urine specimens were obtained for the determination
of clearance of inulin, P04, and sodium. Blood glucose was also
monitored hourly throughout the experiment.
Group 2: role of hyperglycemia (N = 6). Plasma glucose
increased progressively during the suppression of insulin by
somatostatin infusion (Fig. 1) from 93 to a steady level of 137
mg% (third hour) and 143 mg% (fourth hour). Because glucose
in blood [3] and the tubules [9, 10] has been shown to alter P04
reabsorption, independent of plasma insulin, this variable was
examined by infusing dextrose at 400 mg/kg/hr to achieve a
similar degree of hyperglycemia in the 4-hr experimental phase.
Similar clearance studies were performed as in group 1.
Group 3: role of increased natriuresis (N = 6). Fractional
excretion of sodium rose slightly during somatostatin infusion
from a basal value of 11.1% to reach a steady level of 13.5% (see
below). To evaluate the role of this factor, after a basal phase
similar to group 1, the infusion of saline was increased to 15
ml/l00 g/hr over the 4-hr experimental phase.
Group 4: role of plasma insulin. Basal insulin levels (N = 12).
Rats were treated identically to those in group 1. Carotid blood
was drawn directly in ice-chilled containers (six after 40 mm
and six after 80 mm into the basal phase) for determination of
plasma insulin. Glucagon was also measured in four of them.
Insulin during somatostatin suppression (N = 15). Rats were
treated identically as those in group 1. Carotid blood was drawn
(five after 2 hr, five after 4 hr, and five after 6 hr of somatostatin
infusion) for insulin determination. Glucagon was also mea-
sured in four of them.
Insulin levels during combined infusion of somatostatin and
insulin (N = 12). Rats were treated identically to those in group
1 through the sixth hour of somatostatin infusion, over the last 2
hr of which insulin was added. Carotid blood was then obtained
for insulin determination.
Group 5: saline vehicle—time control (N = 6). Two-phase (90
to 120 mm each) recollection micropuncture studies were
performed by techniques previously described [5] during sus-
tained infusion of the saline vehicle at rates identical to those in
group 1.
Group 6: effects of somatostatin on tubular P04 transport (N
= 6). This group was studied similarly to group 5 except for the
addition of somatostatin (10 pg/kg/hr) 30 mm before and
throughout the 2-hr recollection (experimental) phase.
Specimen analysis and calculations
3H-inulin in plasma, urine, and tubular fluid was analyzed by
liquid scintillation counter (Hewlett-Packard, Palo Alto, Cali-
fornia). Calcium, P04, and sodium in plasma and urine were
determined by methods previously described [5, 6]. Tubular
fluid P04 was analyzed by an electron microprobe (ARL).
Except for the substitution for the Cameca model, details of
sample processing and analyses were identical to those in
published reports [5, 11]. Unknowns were accepted only if
correlation coefficients between micro (by the probe) and
macro analysis (by the conventional phosphomolybdate method
described above) exceeded 0.99. Insulin and glucagon were
determined by the laboratory of the University of Michigan
Diabetes Research and Training Center using the double anti-
body RIA techniques previously described [12]. Glucose was
measured by the glucose oxidase method.
Standard formulae were used for the calculations of clearance
of insulin (C1), sodium, and P04 and for the fractional excre-
tion (FE) of sodium and P04. Fractional delivery (FD) of P04
was calculated by the ratio of tubular fluid (TF) to plasma
ultrafiltrable (UF) P04 over that for inulin. All results are
expressed as mean SEM. Data were subject to statistical
analysis using the Student's t test, paired or nonpaired as
appropriate. Differences were considered significant if P values
were less than or equal to 0.05.
Results
Group 1: effects of somatostatin (Fig. 1). There was no
change in GFR during the 4 hr of somatostatin infusion 4.6
0.2 (basal), 4.7 0,3 (first hour), 4.6 0.3 (second hour), and
4.5 0.3 (third hour), 4.4 0.3 mI/mm (fourth hour). This
parameter remained stable in the succeeding 2 hr whether
insulin was added (4.8 0.4 and 4.7 0.2 ml/min) or not (4.5
0.3 and 4.6 0.4 mI/mm). FENa rose from 11.1 0.9 to 13.5
0.8 (second hour), 13.4 0.8 (third hour), and 13.8 0.7%
(fourth hour) (P < 0.05 for all). From a basal level of 93 mg%,
plasma glucose rose to 109 (first hour), 123 (second hour), 137
0.02
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Table 1. Effects of loading with saline and glucose versus somatostatin infusion (mean SE)
P1asma P04
mg%
Plasma glucose
mg%
GFR
mi/mm
C0
lilersimin FEB04 %
B
FENa %
E AB E A B E A B E B E A B E A
Salinea 10.9 10.7 —0.25 — — — 3.8 4.0 140 744 —68 3.8 1.9 —2.0 10.4 13.3c 2.9
Loading ±0.4 ±0.5 ±0.13 ±0.3 ±0.4 ±37 ±20 ±26 ±1.1 ±0.7 ±0.9 ±1.1 ±0.3
(N =6)P valu&' NS NS NS <0.05 NS NS <0.03 <0.001 NS <0.03 <0.001 NS NS NS
Somato-
statina 10.4 10.5 0.14 93 140 47 4.6 4.5 118 297c 180 2.4 6.8c 4.4 11.1 13.6 2.5
(N = 12) ±0.6 ±0.7 ±0.32 ±5 ±7 ±6 ±0.2 ±0.2 ±41 ±63 ±35 ±0.8 ±1.3 ±0.8 ±0.9 ±0.7 ±1.0P value' NS NS NS NS NS NS NS <0.03 NS <0.05 <0.001 NS <0.05 <0.001
Glucosea 11.4 10.7 —0.72 91 143 52 3.9 3.7 150 88 —58 3.9 2.2 —1.9 — — —
Loading ±0.3 ±0.4 ±0.62 ±17 ±4 ±10 ±0.4 ±0.2 ±28 ±18 ±14 ±0.8 ±0.4 ±0.6
(N =6)
Abbreviations: GFR, glomerular filtration rate; Cp4, clearance of P04; FEB04 and FENa, fractional excretion of P04 and Na; B, basal phase; E,
experimental phase.
a Mean values from the third and fourth hours of infusion with saline, SRIF, or glucose.
P values refer to comparison between groups above and below.
P < 0.001 vs. basal within the same group.
' P < 0.05 vs. basal within the same group.
Table 2. Effects of somatostatin on plasma and clearance data
(mean ± SE)
Plasma
UF
GFR
mi/mm
P04
mg%
Cr04
piiterslmin
FEB04
%
Time B 3.2 8.9 140 4.4
Control ±0.4 ±0.8 ±29 ±0.7
(N = 6) E 3.1
±0.3
9.2
±0.6
112
±31
3.5
±0.8
P valuea NS NS NS NS
Somatostatin B 2.9 9.1 128 4.9
(N = 6)
E
±0.3
3.0
±0.4
±1.0
9.0
±0.8
±47
257
±53
±2.1
8.5
±1.8
P valued NS NS <0.05 <0.05
Abbreviations:
Table 1.
UF, ultrafiltrable; other abbreviations are found in
a pvalues refer to differences between basal and experimental phases
within a given group.
(third hour), and 143 mg% (fourth hour) in response to somato-
statin. There was no further change over the next 2 hr or any
significant difference between the two subgroups with or with-
out additional insulin. Plasma P04 was stable throughout the 6
hr of somatostatin infusion. The addition of insulin was associ-
ated with a slight fall to 9.9 ± 0.9 and 9.5 ± 0.9 mg%, but these
values were not different from those rats that did not receive
insulin (10.5 ± 1.5 and 10.3 ± 1.4 mg%). Cp04 rose from 118 to
between 231 and 311 d/min. Continued somatostatin infusion
was associated with a sustained increase in Cr04 330 (fifth hour)
and 342 d/min (sixth hour) whereas the added insulin restored
Cr04 to baseline level 212 (fifth hour) and 146 p1/mm (sixth
hour). During the last hour of insulin infusion, Cp4 was
significantly lower than those rats receiving only somatostatin
(Fig. 1). FEB04 similarly rose during somatostatin infusion (in-
creasing from 2.4 to between 4.8 and 7.1%), which was reduced
by insulin to 2.9% (vs. 7.6 in the subgroup not receiving insulin)
(Fig. 1). Urine glucose by dextrostix (Miles Laboratories,
Elkhart, Indiana) was all negative.
Groups 2 and 3: role of hyperglycemia and increased natri-
uresis (Table 1). To exclude the role of hyperglycemia and
natriuresis, the effects of loading separately with saline and
glucose were compared to somatostatin. There was no change
in plasma P04 or GFR in response to saline loading (Table I).
At comparable increments of FENa (2.9 vs. 2.5 for somato-
statin), there was a slight fall in Cp04 (—68 p1/mm) or no change
in FEB04 (—2.0 ± 0.9%) versus increases associated with
somatostatin. Glucose loading was associated without signifi-
cant alterations in plasma P04 or GFR. At comparable incre-
ments of plasma glucose (52 vs. 47 mg% for somatostatin), there
was a slight fall in both Cr04 (—58 ± 14 p1/mm) and FEB04 (—1.9
± 0.6%) versus the increments in somatostatin-infused rats.
These data indicate that the phosphaturia during somatostatin
administration was not mediated by the concomitant hypergly-
cemia or natriuresis.
Group 4: role of plasma insulin levels. The basal level of
insulin, comparable whether obtained 40 or 80 mm into the
basal phase, was 12.6 ± 3.5 U/mI. Somatostatin infusion
reduced the concentration markedly and by similar degrees
after 2, 4, or 6 hr, to 2,8 ± 1.0 U/mI, P < 0.01. The addition of
exogenous insulin (P < 0.01) increased the plasma level to 30.6
± 12 U/ml, which was not significantly different from the basal
value. The glucagon level was 28 ± 9 pg/ml in the basal period
and was not significantly altered by somatostatin (41 ± 10
pglml).
Groups 5 and 6: tubular effects of somatostatin on P04
transport (Tables 2 and 3). Between the basal and experimental
phases there was no change in both the time control and
somatostatin infused groups for GFR and plasma ultrafiltrable
P04 (Table 2). While Cr04 and FE04 remained stable in the
time control, these parameters rose in response to somatostatin
infusion (128 to 257 p1/mm and 4,9 to 8.5%, respectively; Table
2).
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Similarly, between the basal and experimental phases, there
was no significant difference in TF/P inulin at all three points of
micropuncture in both the time control and the somatostatin-
treated rats (Table 3). TF/UF P04 and FD04 were unchanged in
the time control group. However, somatostatin increased
TF/UF P04 (0.60 to 0.93) and FD04 (32 to 50%) in the late
proximal tubular fluid, indicating an inhibition of P04 transport
in the proximal convoluted tubule. Similar increases in TF/UF
P04 and FD04 were noted for the early distal puncture (0.48 to
0.91 and 13.4 to 28.2%) and late distal puncture (0.43 to 0.86 and
6.4 to 11.8%, respectively), indicating that the proximal inhibi-
tion was still detectable in the distal nephron.
Plasma ultrafiltrable calcium (mg %) fell slightly but signifi-
cantly in all groups (group 1, 3.76 to 3.42; group 2, 3.78 to 3.45;
group 3, 3.85 to 3.5; group 5, 3.73 to 3.44; and group 6, 3.77 to
3.49; group 4, not measured) consistent with the chronic PTX
and the volume-expanded conditions of our preparation. But
the magnitudes of fall were comparable among all groups
measured.
Discussion
The results of the present investigation show that the infusion
of des-Asn5-D-Trp8-D-Ser'3 (d-ATS-SS), an analogue of soma-
tostatin highly selective for insulin, produces a phosphaturia in
the absence of PTH or changes in plasma P04 (Fig. 1 and Table
2). Furthermore, the tubular fluid data suggest that P04 trans-
port is inhibited in the proximal convoluted tubule (Table 3),
exhibiting effects that are independent of fluid reabsorption and
sustained in the distal nephron. It was not possible to attribute
the reduced P04 reabsorption to increased natriuresis ( FENI
of 2.5%) since similar increments in sodium excretion (2.9%)
could not reproduce the phosphaturic effects (Table 1).
Previous work [13] revealed no significant effects of somato-
statin on the phosphaturic or hypocalciuric action of PTH in
PTX dogs. Their negative results could not be attributed to
differences in species [14] or dosages. There are two possible
explanations. First, their studies [13] were not primarily de-
signed to examine the effects of somatostatin, since the infusion
lasted only 20 mm and since no direct comparison between
control and somatostatin was made. Second, their somatostatin
preparations [13] also suppressed other peptides, such as gluca-
gon, recently shown to affect renal P04 reabsorption [15]. Thus,
changes in glucagon level (not determined) might obscure a net
effect on renal P04 handling, especially in the presence of PTE
infusion.
In considering the mechanism for the effects of d-ATS-SS on
tubular P04 transport, several possibilities must be included: (1)
somatostatin per se versus the secondary effects of somato-
statin, viz., (2) changes in adenylate cyclase-cyclic adenosine
monophosphate (cAMP), (3) hyperglycemia, (4) hyperglucagon-
emia, and (5) insulinopenia. Some of these potential mediators
can be readily dismissed for the lack of evidence.
Thus, there is no demonstrable effect of somatostatin on
cAMP concentration or release in rat hepatocytes [16], colon
[17], rabbit ileum [18], or human urine [14], despite earlier
studies in chick renal cells [19]. Although these conflicting data
may simply reflect differences in species, the fact that our
findings were made in PTX rats makes it highly unlikely that
changes in PTH sensitive adenylate cyclase and/or cAMP are
responsible for the phosphaturic effects of somatostatin infu-
sion. This impression is reinforced by the observations that
somatostatin exerted no significant influence on the phosphatu-
nc or hypocalciuric effects of PTE [131.
Previous clearance studies in intact dog [20—22] and man [23—
25] suggested an inhibitory effect of hyperglycemia on P04
reabsorption, but the role of glycosuria could not be dissociat-
ed. In the dog studies [20—22], data interpretation was further
complicated by the hyperphosphatemia. Direct demonstration
of intratubular glucose on proximal tubule P04 transport was
recently made by micropuncture studies [3], microinjection
studies [91, and microperfusion experiments [10]. Again, when
glycosuria was carefully prevented by employing only sub-
threshold hyperglycemia, urinary P04 excretion fell [3], indicat-
ing an enhancement of transport by this maneuver distal to the
proximal convolution.
Glucose loading to reproduce the mild increment in plasma
glucose ( = 52 vs. 47 in the somatostatin experiments) reduced
P04 excretion when glycosuria was absent, confirming the
observations of DeFronzo, Goldberg, and Agus [31 and support-
ing the thesis that glucose increases overall renal P04 reabsorp-
tion despite the proximal inhibition. Therefore, although the
proximal tubule effects of somatostatin could be due to mild
Table 3. Effects of somatostatin on segmental fluid and P04 transport (mean SE)
Late proximal Early distal Late distal
TF
p1tI
TFjPO4 FD04
TFIn ip4 FD04 TF-1-In TFP04 FD0%
Time B 1.87 0.63 34 3.3 0.51 15.0 6.4 0.46 7.5
Control ±0.13 ±0.12 ±4 ±0.2 ±0.09 ±3.8 ±0.6 ±0.08 ±0.9
(N = 6) E 1.90
±0.24
0.69
±0.15
37
±4
3.1
±0.3
0.52
±0.10
16.5
±3.6
6.7
±0.7
0.47
±0.13
7.1
±2.0
p valuesa NS NS NS NS NS NS NS NS NS
Somatostatin B 1.91 0.60 32 3.4 0.48 13.4 6.8 0.43 6.4
(N = 6)
E
±0.12
1.86
±0.10
±0.14
0.93
±0.09
±3
50
±4
±0.4
3.3
±0.4
±0.12
0.91
±0.l5
±4.3
28.2
±5.7
±1.2
7.4
±1.5
±0.17
0.86
±0.23
±2.8
11.8
±2.5
P valuesa NS <0.02 <0.02 NS <0.01 <0.005 NS <0.05 <0.05
Abbreviations: In, inulin; FD04, fractional delivery of P04; other abbreviations are found in Table I.
p values refer to differences between basal and experimental phases within a given group.
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elevation in plasma glucose, the sustained inhibition in the
distal nephron by somatostatin could only be mediated by
factors other than glucose.
Two, the somatostatin-induced inhibition of proximal P04
transport was not associated with diminished fluid reabsorp-
tion, in contrast to the inhibitory effects of subthreshold hyper-
glycemia [31. Three, plasma glucose was equally elevated
between the 4-hr "somatostatin" phase and the 2-hr "somato-
statin + insulin" phase in those six animals infused with insulin
(129 11 vs. 134 10 mg%). Yet mean FEB04 was reduced
significantly in the presence of insulin (6.4 1.3 to 3.5 0.8%,
P < 0.05). Finally, the inhibition by glucose was only observed
when differences in glucose concentration in the plasma [3, 9]
and/or tubular lumen [9] reached or exceeded 70 [3] to 110 mg%
[9], magnitudes two- to threefolds greater than that produced by
SRIF. Similar differences were found necessary to retard P04
uptake by renal brushborder membrane vesicles [26]. In the
isolated rabbit tubule studies by Dennis and Brazy [10], al-
though the presence of glucose retards lumen to bath P04
uptake, no effect could be demonstrated over the range of
glucose concentrations from 108 to 216 mg%. Thus, the weight
of the evidence suggests that changes in plasma insulin best
explains the inhibition of tubular P04 transport by somatostatin
(Table 3), and the enhancement of distal nephron P04 reabsorp-
tion by the hyperinsulinemia [3]. Nevertheless, it should be
acknowledged that we could not definitely exclude the possibili-
ty of a contributory role of hyperglycemia in the phosphaturia
of somatostatin.
Since glucagon in pharmacological doses is phosphaturic [1,
15], associated with inhibition of P04 transport in the proximal
tubule [27], it is possible that the effects of d-ATS-SS were
mediated by glucagon which is not suppressed by our selective
analogue glucagon. However, plasma glucagon did not change
significantly (28 to 41 pg/mI) in our experiments, as was shown
recently in dogs similarly treated [8].
Recent in vitro studies suggest the stimulation of renal
gluconeogenesis (GNG) by somatostatin, that can be abolished
by insulin [28]. Since the rate of GNG has been postulated to
affect proximal tubular P04 transport [29] via changes in the
ratio of oxidized nicotinamide adenine dinucleotide (NAD) to
the reduced form NADH [30, 31], the tubular action of somato-
statin could be explicable by the metabolic effects on GNG.
Indeed, the sites of inhibition by somatostatin correspond to the
major loci of gluconeogeneic activity [32]. However, this thesis
is presently rather speculative without additional studies simul-
taneously measuring transport and metabolism, in view of
recently reported conflicting experimental data [33, 34].
While the intracellular or biochemical mediator for the tubu-
lar effects of somatostatin could not be identified by the present
studies, the data nevertheless are strongly suggestive of a role
for insulin. First, hyperinsulinemia within the physiologic range
(35 to 80 U/ml) due to endogenous release [3] or exogenous
infusion [1—4] has been shown to increase whole kidney P04
reabsorption, the mirror image of the phosphaturic effects of
insulinopenia (2.8 vs. 12.6 iU/ml) produced by somatostatin.
Contrary to previous studies [1—4], where P04 retention could
be attributed to an absolute or relative fall [3] in plasma or
filtered P04, our experiments excluded the role of this variable
(Fig. 1 and Table 2). Our tubular fluid data indicate that
deficiency of insulin, independent of PTH, impairs proximal
tubule P04 transport (Table 3), the converse of the augmented
proximal P04 reabsorption by insulin [3]. Second, when insulin
was replaced in the clearance studies, the phosphaturia was
abolished despite sustained infusion of somatostatin (Fig. I).
Since plasma glucose remained elevated (136 and 132 vs. 93
mg% in the basal phase), changes in plasma insulin were the
only variable altered that could be implicated to reverse the
effects of somatostatin, in contrast to the comparable degree of
hyperglycemia and constant somatostatin infusion.
Third, preliminary reports [35] also suggest enhanced P04
uptake by luminal brushborder membrane vesicles from dogs
infused with insulin. It should be stated that conceivably both
somatostatin and insulin could separately modify P04 reabsorp-
tion, perhaps via some common denominator(s), such as the
rates of GNG and/or the ratio of NAD/NADH, since depres-
sant effects of insulin on renal GNG [28, 36] and intracellular
NAD/NADH ratio [37] have been reported.
It is not possible to establish a direct effect of insulinopenia
on P04 transport in the pars recta because of the increased
proximal rejection (FD04 = 50 vs. 32%) (Table 3). Recent
micropuncture data evaluating the response of this tubular
segment to volume expansion indicate that P04 transport is
load-dependent [38], Sustenance of the proximal inhibition in
the early distal tubular fluid (FD04 = 28.2 vs. 13.4%) is
consistent with impaired transport by the somatostatin in the
pars recta (Table 3). In addition, as a percentage of the
delivered load, reabsorption by this tubular segment was de-
pressed by somatostatin (43 vs. 58%). Though circumstantial,
these results suggest a tubular mechanism for the antiphospha-
turic action of hyperinsulinemia (due to subthreshold hypergly-
cemia) despite the proximal inhibition [3].
Although the role of glycosuria (and osmotic diuresis), cal-
ciuria, and changes in PTH and glucagon could not be dissociat-
ed, chronic insulin therapy in the diabetic human has recently
been shown to be associated with a positive P04 balance via
diminished renal P04 clearance [39, 40].
In summary, selective insulinopenia produced by the infusion
of a somatostatin analogue is associated with impaired P04
transport in the proximal convoluted (and probably the straight)
tubules and increased phosphaturia. These findings are consist-
ent with the concept that basal levels of endogenous insulin are
important in renal P04 homeostasis independent of PTH,
plasma glucose, and P04 concentrations.
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